Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0015674 (
chronic fatigue syndrome
)
2,978
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A prospective randomized study was conducted to determine the optimal schedule of rhG-CSF (recombinant human
granulocyte colony-stimulating factor
). A group of 33 lung cancer patients treated with MVP therapy (mitomycin, vindesine, and cisplatin) were randomly assigned to three groups: an early prophylaxis group in which rhG-CSF was initiated on day 2 of the MVP cycle; a late prophylaxis group in which rhG-CSF was initiated on day 8; and a therapeutic group in which rhG-
CFS
was initiated after the onset of neutropenia. Ten patients who had received MVP therapy without rhG-CSF were also analyzed as a no-support group. The incidence of neutropenia was 80% (16/20 courses) in the early prophylaxis group, 44% (8/18) in the late prophylaxis group, 94% (17/18) in the therapeutic group, and 94% (16/17) in the no-support group. The incidence of neutropenia in the late prophylaxis group was less than in the early prophylaxis group (P<0.05), the therapeutic group (P<0.01), and the no-support group (P<0.01). The late prophylactic rhG-CSF schedule was therefore more effective in countering neutropenia than either the early prophylactic or therapeutic schedule.
...
PMID:Optimal schedule for administering granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in non-small-cell lung cancer. 860 58
Febrile episodes occurring in 29 elderly patients (mean age 75 years) with leukemia, from 1988 to 1993, were reviewed. A febrile episode was defined as a temperature of 38 degrees C or greater for at least 6 hours. The number of febrile episodes was 64. The average was 2.2 febrile episodes per patient. Seventy-two percent of febrile episodes occurred when the patients had neutropenia below 100/microliters, while 16% occurred with neutropenia of 101/microliters to 500/microliters. Causative microorganisms were identified in 48% of total febrile episodes. The most common infectious site was the urinary tract which accounted for 25% of total episodes. Pneumonia and septicemia accounted for 22% of total episodes, respectively. Gram-positive cocci were responsible for 66% of microbiologically documented febrile episodes, while 21% were caused by gram-negative bacilli. Gram-positive cocci, particularly staphylococcus aureus, coagulae-negative staphylococcus and enterococci increased compared with a decade ago in our department.
Granulocyte colony-stimulating factor
(
G-CSF
) was used 12 times for infection. No significant difference in fever amelioration was seen between
G-CSF
and non-G-
CFS
cases.
...
PMID:[Infection in elderly leukemic patients]. 886 21
The pathophysiological significance of seminal cytokines in sperm function is still controversial. We determined the repertoire of cytokines in seminal plasma obtained from men with or without abnormalities in semen and assessed the pathophysiological significance of seminal cytokines. After conventional analysis of semen samples obtained from 86 men, levels of seminal cytokines (interleukin [IL]-1alpha, IL-2, IL-4, IL-6, IL-8, tumor necrosis factor-alpha [TNF-alpha], interferon-gamma,
granulocyte colony-stimulating factor
[G-CSF], macrophage
CFS
[M-CSF]) and granulocyte elastase were measured by an enzyme-linked immunosorbent assay. Leukocytospermia was defined as seminal plasma, which has > or =1000 ng/ml granulocyte elastase. Leukocytospermia was found in nine of 62 of the subjects in the normozoospermic group but in none of the 24 subjects showing abnormal sperm parameters (azoospermia, n=5; oligozoospermia, n=4; asthenozoospermia, n=15). The IL-8 level in the leukocytospermic group was significantly higher than those in the normal and oligozoospermic groups. IL-1alpha and TNF-alpha levels in the leukocytospermic group were significantly higher than those in the normal and asthenozoospermic groups. Although the G-CSF level in the leukocytospermic group was significantly higher than that in the normal group, high levels of M-CSF were detected in all groups. The IL-8 level was strongly correlated with IL-1alpha (r=0.935, P<0.0001) and G-CSF (r=0.916, P<0.0001) levels. Cytokines detected in seminal plasma are associated with the pathogenesis of leukocytospermia but not with the pathogenesis of asthenozoospermia and oligozoospermia.
...
PMID:A repertoire of cytokines in human seminal plasma. 1183 94
In 2005 we reported that transplanted bone marrow-derived cells were engrafted into the olfactory epithelium and then had characteristics of olfactory neuron cells. However, the engraftment rate was far from a practical level.
Granulocyte colony-stimulating factor
(
G-CSF
) is known to mobilize stem cells from the bone marrow into the circulation. To assess the efficacy of
G-CSF
on engrafting transplanted bone marrow-derived cells into the olfactory epithelium, we performed the time window study of
G-CSF
administration. After C57BL/6 mice transplanted with bone marrow cells from GFP mice received selective damage of the olfactory epithelium by methimazole,
G-CSF
was administrated into the recipient mice at different time windows. A statistical analysis demonstrated that the early administration of G-
CFS
was appropriate to increase the engraftment rate of bone marrow-derived cells into the olfactory epithelium. Cells with double-immunostaining for GFP and OMP, GAP43 or cytokeratin were found in the olfactory epithelium of recipient mice. These results suggest that bone marrow-derived cells are engrafted as stem cells of the olfactory tissue and that the early administration of
G-CSF
is more effective to increase the engraftment rate of bone marrow-derived cell into the olfactory epithelium damaged by methimazole.
...
PMID:The early administration of granulocyte colony-stimulating factor increases the engraftment of transplanted bone marrow-derived cells into the olfactory epithelium damaged by methimazole. 2050 66